A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- 27 Jan 2022 Planned number of patients changed from 150 to 84.
- 27 Jan 2022 Planned initiation date changed from 1 Sep 2021 to 1 Feb 2022.
- 13 Aug 2021 New trial record